Celgene and Astellas Venture Management each supplied a portion of the round to bring the Caltech-founded cancer drug developer's lifetime funding to $92m.

US-based cancer and neurodegenerative disease drug developer Cleave Therapeutics closed a $12m series B2 round on Tuesday featuring pharmaceutical firms Celgene and Astellas, the latter through its Astellas Venture Management unit. The round was led by venture capital firm 5AM Ventures and included university-focused investment firm Osage University Partners (OUP), private equity firm Arcus Ventures,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.